Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Merck in Talks for More than $3bn Acquisition of Swiss Biotech MoonLake Immunotherapeutics
Merck, a US pharmaceutical company, has been in discussions regarding a potential acquisition of Swiss biotechnology group MoonLake Immunotherapeutics for over $3 billion. The New Jersey-based drugmaker made a nonbinding offer for MoonLake earlier this year, valuing the company at a premium to its current market value of $2.6 billion. While the initial offer was rebuffed, there is a possibility that talks could be reignited in the future.
MoonLake, founded in 2021 by former McKinsey partner Jorge Santos da Silva, is currently conducting phase-three trials for its lead drug, sonelokimab, as a treatment for hidradenitis suppurativa in adolescents and adults, as well as for psoriatic arthritis. With Morgan Stanley and Goldman Sachs advising MoonLake on the sale process, the company is well-positioned to attract potential buyers.
This move by Merck signals a return to the negotiation table following its acquisition of biotech EyeBio last year. With shareholder pressure mounting on Merck to make strategic acquisitions to boost investor confidence, the company is looking to replenish its drug pipeline amidst challenges such as the upcoming patent expiration of its $30 billion-a-year cancer drug Keytruda.
Merck’s Chief Executive, Rob Davis, has expressed the company’s commitment to pursuing deals despite market volatility. While there is no guarantee that a deal with MoonLake will materialize, the discussions underscore Merck’s strategic focus on expanding its portfolio through strategic acquisitions.
In a landscape where US healthcare dealmaking has slowed due to economic uncertainty and regulatory challenges, the pharmaceutical industry continues to see significant transactions. French drugmaker Sanofi recently announced a $9.5 billion acquisition of Blueprint Medicines, while Bristol Myers Squibb struck an up to $11 billion partnership deal with German drugmaker BioNTech for a cancer treatment in development.
As the pharmaceutical industry navigates through evolving market dynamics, the potential acquisition of MoonLake by Merck represents a strategic move to strengthen its position in the biotechnology sector. With the negotiations ongoing, stakeholders will be closely monitoring developments to see how this deal could shape the future of both companies in the competitive healthcare landscape.
